AASraw is with synthesis and production ability from gram to mass order of Fulvestrant (CAS 129453-61-8), under CGMP regulation and trackable quality control system.

Fulvestrant powder is a synthetic estrogen receptor antagonist. Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines.

AASRAW powder PDF Icon